Skip to Main Content

Paper Details

A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Breast Cancer Res Treat
3
2021
Eribulin, HER2, HER2+, HP, MBC, TP53, eribulin, eribulin mesylate, germline DNA, human, human epidermal growth, human epidermal growth factor receptor 2, metastatic breast cancer, patient, patients, pertuzumab, trastuzumab, tumor, tumor DNA
Author NameAffiliation
Steven J IsakoffMassachusetts General Hospital
Steven J IsakoffHarvard Medical School
Ian E KropDana-Farber Cancer Institute
Ian E KropHarvard Medical School
Nancy U LinDana-Farber Cancer Institute
Nancy U LinHarvard Medical School
Nikhil WagleThe Broad Institute of MIT and Harvard
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleHarvard Medical School
Nikhil WagleThe Broad Institute of MIT and Harvard
Nikhil WagleDana-Farber Cancer Institute
Nikhil WagleHarvard Medical School
  • 1 - 12

Datasets

Release 1.2